Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Rivaroxaban Market

ID: MRFR/HC/37331-HCR
100 Pages
Rahul Gotadki
Last Updated: April 06, 2026

Rivaroxaban Market Research Report By Application (Atrial Fibrillation, Venous Thromboembolism, Coronary Artery Disease, Pulmonary Embolism), By Route of Administration (Oral, Intravenous), By Formulation Type (Tablets, Injectables), By End Use (Hospitals, Ambulatory Surgical Centers, Homecare) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Rivaroxaban Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Application (USD Billion)
  49.     4.1.1 Atrial Fibrillation
  50.     4.1.2 Venous Thromboembolism
  51.     4.1.3 Coronary Artery Disease
  52.     4.1.4 Pulmonary Embolism
  53.   4.2 Healthcare, BY Route of Administration (USD Billion)
  54.     4.2.1 Oral
  55.     4.2.2 Intravenous
  56.   4.3 Healthcare, BY Formulation Type (USD Billion)
  57.     4.3.1 Tablets
  58.     4.3.2 Injectables
  59.   4.4 Healthcare, BY End Use (USD Billion)
  60.     4.4.1 Hospitals
  61.     4.4.2 Ambulatory Surgical Centers
  62.     4.4.3 Homecare
  63.   4.5 Healthcare, BY Region (USD Billion)
  64.     4.5.1 North America
  65.       4.5.1.1 US
  66.       4.5.1.2 Canada
  67.     4.5.2 Europe
  68.       4.5.2.1 Germany
  69.       4.5.2.2 UK
  70.       4.5.2.3 France
  71.       4.5.2.4 Russia
  72.       4.5.2.5 Italy
  73.       4.5.2.6 Spain
  74.       4.5.2.7 Rest of Europe
  75.     4.5.3 APAC
  76.       4.5.3.1 China
  77.       4.5.3.2 India
  78.       4.5.3.3 Japan
  79.       4.5.3.4 South Korea
  80.       4.5.3.5 Malaysia
  81.       4.5.3.6 Thailand
  82.       4.5.3.7 Indonesia
  83.       4.5.3.8 Rest of APAC
  84.     4.5.4 South America
  85.       4.5.4.1 Brazil
  86.       4.5.4.2 Mexico
  87.       4.5.4.3 Argentina
  88.       4.5.4.4 Rest of South America
  89.     4.5.5 MEA
  90.       4.5.5.1 GCC Countries
  91.       4.5.5.2 South Africa
  92.       4.5.5.3 Rest of MEA
  93. 5 SECTION V: COMPETITIVE ANALYSIS
  94.   5.1 Competitive Landscape
  95.     5.1.1 Overview
  96.     5.1.2 Competitive Analysis
  97.     5.1.3 Market share Analysis
  98.     5.1.4 Major Growth Strategy in the Healthcare
  99.     5.1.5 Competitive Benchmarking
  100.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  101.     5.1.7 Key developments and growth strategies
  102.       5.1.7.1 New Product Launch/Service Deployment
  103.       5.1.7.2 Merger & Acquisitions
  104.       5.1.7.3 Joint Ventures
  105.     5.1.8 Major Players Financial Matrix
  106.       5.1.8.1 Sales and Operating Income
  107.       5.1.8.2 Major Players R&D Expenditure. 2023
  108.   5.2 Company Profiles
  109.     5.2.1 Bayer (DE)
  110.       5.2.1.1 Financial Overview
  111.       5.2.1.2 Products Offered
  112.       5.2.1.3 Key Developments
  113.       5.2.1.4 SWOT Analysis
  114.       5.2.1.5 Key Strategies
  115.     5.2.2 Johnson & Johnson (US)
  116.       5.2.2.1 Financial Overview
  117.       5.2.2.2 Products Offered
  118.       5.2.2.3 Key Developments
  119.       5.2.2.4 SWOT Analysis
  120.       5.2.2.5 Key Strategies
  121.     5.2.3 Boehringer Ingelheim (DE)
  122.       5.2.3.1 Financial Overview
  123.       5.2.3.2 Products Offered
  124.       5.2.3.3 Key Developments
  125.       5.2.3.4 SWOT Analysis
  126.       5.2.3.5 Key Strategies
  127.     5.2.4 Pfizer (US)
  128.       5.2.4.1 Financial Overview
  129.       5.2.4.2 Products Offered
  130.       5.2.4.3 Key Developments
  131.       5.2.4.4 SWOT Analysis
  132.       5.2.4.5 Key Strategies
  133.     5.2.5 AstraZeneca (GB)
  134.       5.2.5.1 Financial Overview
  135.       5.2.5.2 Products Offered
  136.       5.2.5.3 Key Developments
  137.       5.2.5.4 SWOT Analysis
  138.       5.2.5.5 Key Strategies
  139.     5.2.6 Sanofi (FR)
  140.       5.2.6.1 Financial Overview
  141.       5.2.6.2 Products Offered
  142.       5.2.6.3 Key Developments
  143.       5.2.6.4 SWOT Analysis
  144.       5.2.6.5 Key Strategies
  145.     5.2.7 Bristol-Myers Squibb (US)
  146.       5.2.7.1 Financial Overview
  147.       5.2.7.2 Products Offered
  148.       5.2.7.3 Key Developments
  149.       5.2.7.4 SWOT Analysis
  150.       5.2.7.5 Key Strategies
  151.     5.2.8 Novartis (CH)
  152.       5.2.8.1 Financial Overview
  153.       5.2.8.2 Products Offered
  154.       5.2.8.3 Key Developments
  155.       5.2.8.4 SWOT Analysis
  156.       5.2.8.5 Key Strategies
  157.   5.3 Appendix
  158.     5.3.1 References
  159.     5.3.2 Related Reports
  160. 6 LIST OF FIGURES
  161.   6.1 MARKET SYNOPSIS
  162.   6.2 NORTH AMERICA MARKET ANALYSIS
  163.   6.3 US MARKET ANALYSIS BY APPLICATION
  164.   6.4 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  165.   6.5 US MARKET ANALYSIS BY FORMULATION TYPE
  166.   6.6 US MARKET ANALYSIS BY END USE
  167.   6.7 CANADA MARKET ANALYSIS BY APPLICATION
  168.   6.8 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  169.   6.9 CANADA MARKET ANALYSIS BY FORMULATION TYPE
  170.   6.10 CANADA MARKET ANALYSIS BY END USE
  171.   6.11 EUROPE MARKET ANALYSIS
  172.   6.12 GERMANY MARKET ANALYSIS BY APPLICATION
  173.   6.13 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  174.   6.14 GERMANY MARKET ANALYSIS BY FORMULATION TYPE
  175.   6.15 GERMANY MARKET ANALYSIS BY END USE
  176.   6.16 UK MARKET ANALYSIS BY APPLICATION
  177.   6.17 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  178.   6.18 UK MARKET ANALYSIS BY FORMULATION TYPE
  179.   6.19 UK MARKET ANALYSIS BY END USE
  180.   6.20 FRANCE MARKET ANALYSIS BY APPLICATION
  181.   6.21 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  182.   6.22 FRANCE MARKET ANALYSIS BY FORMULATION TYPE
  183.   6.23 FRANCE MARKET ANALYSIS BY END USE
  184.   6.24 RUSSIA MARKET ANALYSIS BY APPLICATION
  185.   6.25 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  186.   6.26 RUSSIA MARKET ANALYSIS BY FORMULATION TYPE
  187.   6.27 RUSSIA MARKET ANALYSIS BY END USE
  188.   6.28 ITALY MARKET ANALYSIS BY APPLICATION
  189.   6.29 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  190.   6.30 ITALY MARKET ANALYSIS BY FORMULATION TYPE
  191.   6.31 ITALY MARKET ANALYSIS BY END USE
  192.   6.32 SPAIN MARKET ANALYSIS BY APPLICATION
  193.   6.33 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  194.   6.34 SPAIN MARKET ANALYSIS BY FORMULATION TYPE
  195.   6.35 SPAIN MARKET ANALYSIS BY END USE
  196.   6.36 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
  197.   6.37 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  198.   6.38 REST OF EUROPE MARKET ANALYSIS BY FORMULATION TYPE
  199.   6.39 REST OF EUROPE MARKET ANALYSIS BY END USE
  200.   6.40 APAC MARKET ANALYSIS
  201.   6.41 CHINA MARKET ANALYSIS BY APPLICATION
  202.   6.42 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  203.   6.43 CHINA MARKET ANALYSIS BY FORMULATION TYPE
  204.   6.44 CHINA MARKET ANALYSIS BY END USE
  205.   6.45 INDIA MARKET ANALYSIS BY APPLICATION
  206.   6.46 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  207.   6.47 INDIA MARKET ANALYSIS BY FORMULATION TYPE
  208.   6.48 INDIA MARKET ANALYSIS BY END USE
  209.   6.49 JAPAN MARKET ANALYSIS BY APPLICATION
  210.   6.50 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  211.   6.51 JAPAN MARKET ANALYSIS BY FORMULATION TYPE
  212.   6.52 JAPAN MARKET ANALYSIS BY END USE
  213.   6.53 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
  214.   6.54 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  215.   6.55 SOUTH KOREA MARKET ANALYSIS BY FORMULATION TYPE
  216.   6.56 SOUTH KOREA MARKET ANALYSIS BY END USE
  217.   6.57 MALAYSIA MARKET ANALYSIS BY APPLICATION
  218.   6.58 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  219.   6.59 MALAYSIA MARKET ANALYSIS BY FORMULATION TYPE
  220.   6.60 MALAYSIA MARKET ANALYSIS BY END USE
  221.   6.61 THAILAND MARKET ANALYSIS BY APPLICATION
  222.   6.62 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  223.   6.63 THAILAND MARKET ANALYSIS BY FORMULATION TYPE
  224.   6.64 THAILAND MARKET ANALYSIS BY END USE
  225.   6.65 INDONESIA MARKET ANALYSIS BY APPLICATION
  226.   6.66 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  227.   6.67 INDONESIA MARKET ANALYSIS BY FORMULATION TYPE
  228.   6.68 INDONESIA MARKET ANALYSIS BY END USE
  229.   6.69 REST OF APAC MARKET ANALYSIS BY APPLICATION
  230.   6.70 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  231.   6.71 REST OF APAC MARKET ANALYSIS BY FORMULATION TYPE
  232.   6.72 REST OF APAC MARKET ANALYSIS BY END USE
  233.   6.73 SOUTH AMERICA MARKET ANALYSIS
  234.   6.74 BRAZIL MARKET ANALYSIS BY APPLICATION
  235.   6.75 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  236.   6.76 BRAZIL MARKET ANALYSIS BY FORMULATION TYPE
  237.   6.77 BRAZIL MARKET ANALYSIS BY END USE
  238.   6.78 MEXICO MARKET ANALYSIS BY APPLICATION
  239.   6.79 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  240.   6.80 MEXICO MARKET ANALYSIS BY FORMULATION TYPE
  241.   6.81 MEXICO MARKET ANALYSIS BY END USE
  242.   6.82 ARGENTINA MARKET ANALYSIS BY APPLICATION
  243.   6.83 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  244.   6.84 ARGENTINA MARKET ANALYSIS BY FORMULATION TYPE
  245.   6.85 ARGENTINA MARKET ANALYSIS BY END USE
  246.   6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
  247.   6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  248.   6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY FORMULATION TYPE
  249.   6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USE
  250.   6.90 MEA MARKET ANALYSIS
  251.   6.91 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
  252.   6.92 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  253.   6.93 GCC COUNTRIES MARKET ANALYSIS BY FORMULATION TYPE
  254.   6.94 GCC COUNTRIES MARKET ANALYSIS BY END USE
  255.   6.95 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
  256.   6.96 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  257.   6.97 SOUTH AFRICA MARKET ANALYSIS BY FORMULATION TYPE
  258.   6.98 SOUTH AFRICA MARKET ANALYSIS BY END USE
  259.   6.99 REST OF MEA MARKET ANALYSIS BY APPLICATION
  260.   6.100 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  261.   6.101 REST OF MEA MARKET ANALYSIS BY FORMULATION TYPE
  262.   6.102 REST OF MEA MARKET ANALYSIS BY END USE
  263.   6.103 KEY BUYING CRITERIA OF HEALTHCARE
  264.   6.104 RESEARCH PROCESS OF MRFR
  265.   6.105 DRO ANALYSIS OF HEALTHCARE
  266.   6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  267.   6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  268.   6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
  269.   6.109 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
  270.   6.110 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
  271.   6.111 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
  272.   6.112 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
  273.   6.113 HEALTHCARE, BY FORMULATION TYPE, 2024 (% SHARE)
  274.   6.114 HEALTHCARE, BY FORMULATION TYPE, 2024 TO 2035 (USD Billion)
  275.   6.115 HEALTHCARE, BY END USE, 2024 (% SHARE)
  276.   6.116 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Billion)
  277.   6.117 BENCHMARKING OF MAJOR COMPETITORS
  278. 7 LIST OF TABLES
  279.   7.1 LIST OF ASSUMPTIONS
  280.     7.1.1
  281.   7.2 North America MARKET SIZE ESTIMATES; FORECAST
  282.     7.2.1 BY APPLICATION, 2025-2035 (USD Billion)
  283.     7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  284.     7.2.3 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  285.     7.2.4 BY END USE, 2025-2035 (USD Billion)
  286.   7.3 US MARKET SIZE ESTIMATES; FORECAST
  287.     7.3.1 BY APPLICATION, 2025-2035 (USD Billion)
  288.     7.3.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  289.     7.3.3 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  290.     7.3.4 BY END USE, 2025-2035 (USD Billion)
  291.   7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  292.     7.4.1 BY APPLICATION, 2025-2035 (USD Billion)
  293.     7.4.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  294.     7.4.3 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  295.     7.4.4 BY END USE, 2025-2035 (USD Billion)
  296.   7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  297.     7.5.1 BY APPLICATION, 2025-2035 (USD Billion)
  298.     7.5.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  299.     7.5.3 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  300.     7.5.4 BY END USE, 2025-2035 (USD Billion)
  301.   7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  302.     7.6.1 BY APPLICATION, 2025-2035 (USD Billion)
  303.     7.6.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  304.     7.6.3 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  305.     7.6.4 BY END USE, 2025-2035 (USD Billion)
  306.   7.7 UK MARKET SIZE ESTIMATES; FORECAST
  307.     7.7.1 BY APPLICATION, 2025-2035 (USD Billion)
  308.     7.7.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  309.     7.7.3 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  310.     7.7.4 BY END USE, 2025-2035 (USD Billion)
  311.   7.8 France MARKET SIZE ESTIMATES; FORECAST
  312.     7.8.1 BY APPLICATION, 2025-2035 (USD Billion)
  313.     7.8.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  314.     7.8.3 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  315.     7.8.4 BY END USE, 2025-2035 (USD Billion)
  316.   7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  317.     7.9.1 BY APPLICATION, 2025-2035 (USD Billion)
  318.     7.9.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  319.     7.9.3 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  320.     7.9.4 BY END USE, 2025-2035 (USD Billion)
  321.   7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  322.     7.10.1 BY APPLICATION, 2025-2035 (USD Billion)
  323.     7.10.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  324.     7.10.3 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  325.     7.10.4 BY END USE, 2025-2035 (USD Billion)
  326.   7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  327.     7.11.1 BY APPLICATION, 2025-2035 (USD Billion)
  328.     7.11.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  329.     7.11.3 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  330.     7.11.4 BY END USE, 2025-2035 (USD Billion)
  331.   7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  332.     7.12.1 BY APPLICATION, 2025-2035 (USD Billion)
  333.     7.12.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  334.     7.12.3 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  335.     7.12.4 BY END USE, 2025-2035 (USD Billion)
  336.   7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  337.     7.13.1 BY APPLICATION, 2025-2035 (USD Billion)
  338.     7.13.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  339.     7.13.3 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  340.     7.13.4 BY END USE, 2025-2035 (USD Billion)
  341.   7.14 China MARKET SIZE ESTIMATES; FORECAST
  342.     7.14.1 BY APPLICATION, 2025-2035 (USD Billion)
  343.     7.14.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  344.     7.14.3 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  345.     7.14.4 BY END USE, 2025-2035 (USD Billion)
  346.   7.15 India MARKET SIZE ESTIMATES; FORECAST
  347.     7.15.1 BY APPLICATION, 2025-2035 (USD Billion)
  348.     7.15.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  349.     7.15.3 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  350.     7.15.4 BY END USE, 2025-2035 (USD Billion)
  351.   7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  352.     7.16.1 BY APPLICATION, 2025-2035 (USD Billion)
  353.     7.16.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  354.     7.16.3 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  355.     7.16.4 BY END USE, 2025-2035 (USD Billion)
  356.   7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  357.     7.17.1 BY APPLICATION, 2025-2035 (USD Billion)
  358.     7.17.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  359.     7.17.3 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  360.     7.17.4 BY END USE, 2025-2035 (USD Billion)
  361.   7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  362.     7.18.1 BY APPLICATION, 2025-2035 (USD Billion)
  363.     7.18.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  364.     7.18.3 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  365.     7.18.4 BY END USE, 2025-2035 (USD Billion)
  366.   7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  367.     7.19.1 BY APPLICATION, 2025-2035 (USD Billion)
  368.     7.19.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  369.     7.19.3 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  370.     7.19.4 BY END USE, 2025-2035 (USD Billion)
  371.   7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  372.     7.20.1 BY APPLICATION, 2025-2035 (USD Billion)
  373.     7.20.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  374.     7.20.3 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  375.     7.20.4 BY END USE, 2025-2035 (USD Billion)
  376.   7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  377.     7.21.1 BY APPLICATION, 2025-2035 (USD Billion)
  378.     7.21.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  379.     7.21.3 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  380.     7.21.4 BY END USE, 2025-2035 (USD Billion)
  381.   7.22 South America MARKET SIZE ESTIMATES; FORECAST
  382.     7.22.1 BY APPLICATION, 2025-2035 (USD Billion)
  383.     7.22.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  384.     7.22.3 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  385.     7.22.4 BY END USE, 2025-2035 (USD Billion)
  386.   7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  387.     7.23.1 BY APPLICATION, 2025-2035 (USD Billion)
  388.     7.23.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  389.     7.23.3 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  390.     7.23.4 BY END USE, 2025-2035 (USD Billion)
  391.   7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  392.     7.24.1 BY APPLICATION, 2025-2035 (USD Billion)
  393.     7.24.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  394.     7.24.3 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  395.     7.24.4 BY END USE, 2025-2035 (USD Billion)
  396.   7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  397.     7.25.1 BY APPLICATION, 2025-2035 (USD Billion)
  398.     7.25.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  399.     7.25.3 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  400.     7.25.4 BY END USE, 2025-2035 (USD Billion)
  401.   7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  402.     7.26.1 BY APPLICATION, 2025-2035 (USD Billion)
  403.     7.26.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  404.     7.26.3 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  405.     7.26.4 BY END USE, 2025-2035 (USD Billion)
  406.   7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  407.     7.27.1 BY APPLICATION, 2025-2035 (USD Billion)
  408.     7.27.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  409.     7.27.3 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  410.     7.27.4 BY END USE, 2025-2035 (USD Billion)
  411.   7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  412.     7.28.1 BY APPLICATION, 2025-2035 (USD Billion)
  413.     7.28.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  414.     7.28.3 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  415.     7.28.4 BY END USE, 2025-2035 (USD Billion)
  416.   7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  417.     7.29.1 BY APPLICATION, 2025-2035 (USD Billion)
  418.     7.29.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  419.     7.29.3 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  420.     7.29.4 BY END USE, 2025-2035 (USD Billion)
  421.   7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  422.     7.30.1 BY APPLICATION, 2025-2035 (USD Billion)
  423.     7.30.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  424.     7.30.3 BY FORMULATION TYPE, 2025-2035 (USD Billion)
  425.     7.30.4 BY END USE, 2025-2035 (USD Billion)
  426.   7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  427.     7.31.1
  428.   7.32 ACQUISITION/PARTNERSHIP
  429.     7.32.1

Healthcare Market Segmentation

Healthcare By Application (USD Billion, 2025-2035)

  • Atrial Fibrillation
  • Venous Thromboembolism
  • Coronary Artery Disease
  • Pulmonary Embolism

Healthcare By Route of Administration (USD Billion, 2025-2035)

  • Oral
  • Intravenous

Healthcare By Formulation Type (USD Billion, 2025-2035)

  • Tablets
  • Injectables

Healthcare By End Use (USD Billion, 2025-2035)

  • Hospitals
  • Ambulatory Surgical Centers
  • Homecare

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions